WO2013038200A3 - Neurodevelopmental disorders - Google Patents

Neurodevelopmental disorders Download PDF

Info

Publication number
WO2013038200A3
WO2013038200A3 PCT/GB2012/052278 GB2012052278W WO2013038200A3 WO 2013038200 A3 WO2013038200 A3 WO 2013038200A3 GB 2012052278 W GB2012052278 W GB 2012052278W WO 2013038200 A3 WO2013038200 A3 WO 2013038200A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurodevelopmental disorders
methods
disorders
ameliorating
medicaments
Prior art date
Application number
PCT/GB2012/052278
Other languages
French (fr)
Other versions
WO2013038200A2 (en
Inventor
Ayana Alice GIBBS
Simon Edward Ward
Lewis Elliot PENNICOTT
Original Assignee
The University Of Sussex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Sussex filed Critical The University Of Sussex
Publication of WO2013038200A2 publication Critical patent/WO2013038200A2/en
Publication of WO2013038200A3 publication Critical patent/WO2013038200A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Abstract

The invention provides pharmaceutical compositions, medicaments and methods for use in preventing, ameliorating or treating neurodevelopmental disorders. The invention extends to novel synthetic methods for preparing active agents useful in the treatment of neurodevelopmental disorders.
PCT/GB2012/052278 2011-09-15 2012-09-14 Neurodevelopmental disorders WO2013038200A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1115977.9 2011-09-15
GB1115977.9A GB2503187A (en) 2011-09-15 2011-09-15 Composition for use in the treatment of neurodevelopmental disorders

Publications (2)

Publication Number Publication Date
WO2013038200A2 WO2013038200A2 (en) 2013-03-21
WO2013038200A3 true WO2013038200A3 (en) 2013-06-27

Family

ID=44908638

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2012/052278 WO2013038200A2 (en) 2011-09-15 2012-09-14 Neurodevelopmental disorders

Country Status (2)

Country Link
GB (1) GB2503187A (en)
WO (1) WO2013038200A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE055000T2 (en) 2015-02-27 2021-10-28 Dechra Ltd Stimulation of appetite, management of weight loss, and treatment of anorexia in dogs and cats
WO2017083739A1 (en) 2015-11-13 2017-05-18 The Trustees Of Columbia University In The City Of New York A method for predicting a subject's response to valproic acid therapy
WO2020065090A2 (en) * 2018-09-28 2020-04-02 Medizinische Hochschule Hannover (Mhh) Treatment of dementia-associated tauopathies

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2201414A (en) * 1984-04-24 1988-09-01 Glaxo Group Ltd 1, 4-Benzodioxane-2,3-dimethanols
WO1994008579A1 (en) * 1992-10-08 1994-04-28 New York University β-AGONIST, α1-AGONIST, AND/OR α2-ANTAGONIST TREATMENT OF NEURODEGENERATIVE DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA
WO2001055132A1 (en) * 2000-01-28 2001-08-02 Novartis Ag 1,3-disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists
WO2003082866A1 (en) * 2002-04-03 2003-10-09 Orion Corporation Polycyclic compounds as potent alpha2-adrenoceptor antagonists
WO2004011031A1 (en) * 2002-07-29 2004-02-05 Potomac, Pharma, Llc. Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic
WO2008019431A1 (en) * 2006-08-14 2008-02-21 Brc Operations Pty Limited Method and compositions for simultaneously regulating memory and mood

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3760089A (en) 1972-04-27 1973-09-18 Westinghouse Electric Corp Electrical bushing assembly having resilient means enclosed within sealing means
GB8526209D0 (en) 1985-10-23 1985-11-27 Glaxo Group Ltd Chemical process
GB8828032D0 (en) * 1988-12-01 1989-01-05 Glaxo Group Ltd Medicaments
GB8911166D0 (en) * 1989-05-16 1989-07-05 Glaxo Group Ltd Medicaments
GB2244431A (en) * 1990-05-31 1991-12-04 Farmos Oy Treatment of age related memory impairment and other cognitive disorders
GB9012469D0 (en) * 1990-06-05 1990-07-25 Glaxo Group Ltd Medicaments
GB9119466D0 (en) 1991-09-12 1991-10-23 Glaxo Group Ltd Chemical compounds
WO2007148185A2 (en) 2006-06-21 2007-12-27 Pfizer Products Inc. Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2201414A (en) * 1984-04-24 1988-09-01 Glaxo Group Ltd 1, 4-Benzodioxane-2,3-dimethanols
WO1994008579A1 (en) * 1992-10-08 1994-04-28 New York University β-AGONIST, α1-AGONIST, AND/OR α2-ANTAGONIST TREATMENT OF NEURODEGENERATIVE DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA
WO2001055132A1 (en) * 2000-01-28 2001-08-02 Novartis Ag 1,3-disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists
WO2003082866A1 (en) * 2002-04-03 2003-10-09 Orion Corporation Polycyclic compounds as potent alpha2-adrenoceptor antagonists
WO2004011031A1 (en) * 2002-07-29 2004-02-05 Potomac, Pharma, Llc. Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic
WO2008019431A1 (en) * 2006-08-14 2008-02-21 Brc Operations Pty Limited Method and compositions for simultaneously regulating memory and mood

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GIAKOUMAKI STELLA G ET AL: "Improvement of Prepulse Inhibition and Executive Function by the COMT Inhibitor Tolcapone Depends on COMT Val(158)Met Polymorphism", NEUROPSYCHOPHARMACOLOGY, vol. 33, no. 13, December 2008 (2008-12-01), pages 3058 - 3068, XP002688113, ISSN: 0893-133X *
GIBBS A A ET AL: "Deletion variant of +/-2b-adrenergic receptor gene moderates the effect of COMT val<158>met polymorphism on episodic memory performance", EUROPEAN NEUROPSYCHOPHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, AMSTERDAM, NL, vol. 20, no. 4, 1 April 2010 (2010-04-01), pages 272 - 275, XP026930262, ISSN: 0924-977X, [retrieved on 20100127], DOI: 10.1016/J.EURONEURO.2009.12.007 *
KOHLI UTKARSH ET AL: "Effects of variation in the human alpha2A- and alpha2C-adrenoceptor genes on cognitive tasks and pain perception.", EUROPEAN JOURNAL OF PAIN (LONDON, ENGLAND) FEB 2010, vol. 14, no. 2, February 2010 (2010-02-01), pages 154 - 159, XP002688114, ISSN: 1532-2149 *
SAHAKIAN B J ET AL: "Selective enhancement of executive function by idazoxan in a patient with dementia of the frontal lobe type.", JOURNAL OF NEUROLOGY, NEUROSURGERY, AND PSYCHIATRY JAN 1994, vol. 57, no. 1, January 1994 (1994-01-01), pages 120 - 121, XP002688112, ISSN: 0022-3050 *
SCULLION G A ET AL: "Chronic treatment with the-adrenoceptor antagonist fluparoxan prevents age-related deficits in spatial working memory in APPPS1 transgenic mice without altering -amyloid plaque load or astrocytosis", NEUROPHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 60, no. 2, 3 September 2010 (2010-09-03), pages 223 - 234, XP028365576, ISSN: 0028-3908, [retrieved on 20100917], DOI: 10.1016/J.NEUROPHARM.2010.09.002 *
WEICKERT T W ET AL: "Catechol-O-methyltransferase val<108/158>met genotype predicts working memory response to antipsychotic medications", BIOLOGICAL PSYCHIATRY, ELSEVIER SCIENCE, NEW YORK, NY, US, vol. 56, no. 9, 1 November 2004 (2004-11-01), pages 677 - 682, XP004619801, ISSN: 0006-3223, DOI: 10.1016/J.BIOPSYCH.2004.08.012 *

Also Published As

Publication number Publication date
WO2013038200A2 (en) 2013-03-21
GB201115977D0 (en) 2011-10-26
GB2503187A (en) 2013-12-25

Similar Documents

Publication Publication Date Title
IN2014DN09434A (en)
MX2013011908A (en) Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors.
MX344238B (en) Tetrazole compounds and methods of making and using same.
MX343687B (en) Tricyclic sulfonamide compounds and methods of making and using same.
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
WO2013169864A3 (en) TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
WO2012062925A3 (en) Compounds and methods for treating pain
TN2012000428A1 (en) Bisaryl-bonded aryltriazolones and use thereof
MX2014008705A (en) Tricyclic sulfone compounds and methods of making and using same.
PH12015500724A1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
WO2012154679A8 (en) Tricyclic pyrazole sulfonamide compounds and methods of making and using same
MX2013012053A (en) Inhibitors of viral replication, their process of preparation and their therapeutical uses.
MX2014008706A (en) Tricyclic sulfonamide compounds and methods of making and using same.
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
WO2012158672A3 (en) Compounds for use in treatment of mucositis
PH12014502623B1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
MX2015005732A (en) Tricyclic compounds and methods of making and using same.
HK1197235A1 (en) Dihydropyrazoles, pharmaceutical compositions thereof and their use for the treatment of fertility disorders
MX366829B (en) Itraconazole compositions and dosage forms, and methods of using the same.
MX2015005733A (en) Tricyclic compounds for use in the treatment and/or control of obesity.
MX2013002261A (en) Substituted n-phenethyltriazoloneacetamides and use thereof.
WO2013038200A3 (en) Neurodevelopmental disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12761792

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12761792

Country of ref document: EP

Kind code of ref document: A2